Yüklüyor......
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
BRAF and MEK inhibitors have improved outcomes for patients with BRAF-mutant melanoma, but their efficacy is limited by both intrinsic and acquired resistances. Activation of the PI3K pathway can mediate resistance to these agents, providing a strong rationale for combination therapy in melanoma. He...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4468830/ https://ncbi.nlm.nih.gov/pubmed/26137449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2015.00135 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|